| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $6,179,975 | 2 | 67 |
Sells | $12,869 | 1 | 33 |
| AKKARAJU SRINIVAS | 2 | $6.18M | 0 | $0 | $6.18M | |
| Hagen Brett R | Chief Accounting Officer | 0 | $0 | 1 | $12,869 | $-12,869 |
Kalaris Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development and commercialization of treatments for prevalent retinal diseases. It develops TH103, a clinical-stage anti-vascular endothelial growth factor (VEGF) drug for the treatment of neovascular age-related macular degeneration (nAMD), as well as for the treatment of other exudative and neovascular retinal diseases.
Over the last 12 months, insiders at Kalaris Therapeutics Inc have bought $6.18M and sold $12,869 worth of Kalaris Therapeutics Inc stock.
On average, over the past 5 years, insiders at Kalaris Therapeutics Inc have bought $6.18M and sold $10,502 worth of stock each year.
Highest buying activity among insiders over the last 12 months: AKKARAJU SRINIVAS () — $6.18M.
The last purchase of 244,300 shares for transaction amount of $1.18M was made by AKKARAJU SRINIVAS () on 2026‑05‑20.
| 2026-05-20 | AKKARAJU SRINIVAS | 244,300 1.3062% | $4.83 | $1.18M | -17.18% | |||
| 2026-03-20 | Sale | Hagen Brett R | Chief Accounting Officer | 1,915 0.0105% | $6.72 | $12,869 | -36.07% | |
| 2025-12-18 | AKKARAJU SRINIVAS | 479,847 3.0554% | $10.42 | $5M | -54.03% | |||
| 2025-03-26 | Sale | Hagen Brett R | Chief Accounting Officer | 907 0.005% | $8.97 | $8,135 | -41.26% |
| Increased Positions | 34 | +100% | 5M | +40.86% |
| Decreased Positions | 12 | -35.29% | 629,529 | -4.76% |
| New Positions | 24 | New | 4M | New |
| Sold Out Positions | 5 | Sold Out | 444,043 | Sold Out |
| Total Postitions | 56 | +64.71% | 18M | +36.1% |